Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities

Key Points

• The aim is to explore how sodium-glucose cotransporter-2 inhibitors affect heart failure across different racial groups.
• Randomized trial design
• Comparison of heart failure outcomes among different racial groups
• Analysis of treatment effects using sodium-glucose cotransporter-2 inhibitors
• Sodium-glucose cotransporter-2 inhibitors showed improved heart failure outcomes in Black patients (HR 0.76, 95% CI 0.60-0.94, p=0.02)
• Disparities in heart failure outcomes were notably reduced with treatment in Hispanic populations
• Overall, the use of these inhibitors highlights important differences in response to treatment across racial demographics